Home » FDA APPROVES NOVARTIS' TREATMENT FOR DEMENTIA IN PARKINSON'S DISEASE
FDA APPROVES NOVARTIS' TREATMENT FOR DEMENTIA IN PARKINSON'S DISEASE
July 6, 2006
The FDA has approved Novartis' drug Exelon for the treatment of mild-to-moderate dementia associated with Parkinson's disease. The medication was previously approved for the treatment of mild-to-moderate dementia caused by Alzheimer's disease.
The new approval is based on the results of a randomized clinical trial in which Exelon was shown to be significantly more efficacious than placebo in 541 Parkinson's disease patients with dementia.
Exelon sales were $172 million in 2005, said the company.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct